Kyverna Therapeutics, Inc. (KYTX) stock
KYTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$4.70−0.06 (-1.26%)
Close on Nov 17, 2026Market cap $290.66MP/E –Yield –
Earnings
Kyverna Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Mar 25, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
-$0.68
-$0.85 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Kyverna Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 25, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 12, 2026before the open | – | – | -$0.68 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 11, 2026during market hours | – | – | -$0.63 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 12, 2026during market hours | – | – | -$0.66 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 26, 2026during market hours | – | – | -$0.80 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 12, 2025during market hours | – | – | -$0.85 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 12, 2025during market hours | – | – | -$0.97 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 13, 2025during market hours | – | – | -$1.03 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 27, 2025during market hours | – | – | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 13, 2024during market hours | – | – | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 12, 2024during market hours | – | – | -$0.67 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 14, 2024during market hours | – | – | -$1.12 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 26, 2024during market hours | – | – | – | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Kyverna Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Kyverna Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Kyverna Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Update
- News
- Results
- News
- Update
- Update
- Update
- Results
- News
- News
- Results
- News
See a number that looks wrong?